GLP-1
Kriya Therapeutics, based in Redwood City, Calif. and Research Triangle Park, NC, closed on a Series B financing worth $100 million.
It was another busy week for clinical trial news ahead of the July 4 holiday in the U.S. Here’s a look.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
The groundbreaking success of the mRNA vaccines for COVID-19 by Pfizer-BioNTech and Moderna has led the way for other companies with a vested interest in vaccine development.
Eli Lilly and Novo Nordisk published their data in The Lancet Diabetes & Endocrinology and presented them at the ADA conference.
It was another busy week of clinical trial announcements. Here’s a look.
Seattle-based clinical-stage biopharmaceutical company Lumen Bioscience is teaming up with Novo Nordisk to explore research and development opportunities within obesity, among other metabolic disorders.
Wegovy is the first and only once-weekly GLP-1 receptor agonist that’s been approved for weight control in people living with obesity. This is the same drug used to treat type 2 diabetes.
Eli Lilly’s SURPASS-4 trial program shows tirzepatide, significantly reduced blood glucose levels and body weight better than insulin glargine in adult patients with type 2 diabetes.
Recent work by the PolyPeptide Group, a Swiss contract manufacturing organization (CMO), shows that green chemistry is not only feasible, but also is economically sound.
PRESS RELEASES